Compound ID | 1955

Update compound information

Nacubactam

Synonym(s): OP0595  |  RG6080  |  FPI-1459

Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])

Spectrum of activity: Gram-negative
Details of activity: DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D and inhibits penicillin binding protein 2 in Enterobacteriaceae
Combined with other compounds: Yes
Description: Synthetic compound. In clinical development in fixed combination with meropenem
Institute where first reported: Fedora Pharmaceuticals, Meiji Seika Pharma, Roche
Year first mentioned: 2015
Highest developmental phase: Phase 3 (NCT05905055)
Development status: Active (as of 2022)
Chemical structure(s):
Click here for structure editor
Molecular weight: 324.31
Iso. SMILES: C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NOCCN
InChI Key: RSBPYSTVZQAADE-RQJHMYQMSA-N
Can. SMILES: C1C[C@@H](C(=O)NOCCN)N2C[C@@H]1N(C2=O)OS(=O)(=O)O
InChI: InChI=1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)/t6-,7+/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/Nacubactam
Guide to Pharmacology: nacubactam
Citations:
  • https://journals.asm.org/doi/10.1128/AAC.02229-19
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532682/
  • https://pubmed.ncbi.nlm.nih.gov/30590470/

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.